PT -期刊文章盟迈克尔Yochelson AU -迈克尔奶油AU -杰弗里云盟-彼得Kossmehl AU -杰拉德弗朗西斯科AU - Anthony Ward盟Joerg Wissel AU -毛罗·Zampolini盟梅根Loven AU -阿卜杜拉Abouihia盟亚历山德拉花茎甘蓝AU -利奥波德Saltuari TI -鞘内巴氯芬疗法可以减少疼痛和改善生活质量比传统医疗管理严重中风后痉挛状态:姐妹研究(P5.014) DP - 2018年4月10 TA -神经病学PG - P5.014 VI - 90 IP - 15补充4099 - //www.ez-admanager.com/content/90/15_Supplement/P5.014.short 4100 - //www.ez-admanager.com/content/90/15_Supplement/P5.014.full所以Neurology2018 4月10;首页90 AB -目的:比较肌张力降低,减少疼痛和生活质量的改善从基线到6月间鞘内巴氯芬(髂胫)疗法和传统医学管理(CMM)口服antispastic治疗中风后痉挛状态。背景:姐妹是第一个多中心随机对照试验比较国际旅游展的疗法在中风后痉挛状态CMM。设计/方法:60中风患者在≥2四肢痉挛状态,Ashworth规模(AS)分数≥3至少2影响下肢的肌肉群随机或CMM国际旅游展的集团。两组接受理疗。结果:减少平均(SD)影响下肢胫组为0.99(0.75)和0.43(0.72)在CMM病人(术中,0.05)。意味着在上肢下降了0.66(0.59)和0.17(0.70)和CMM国际旅游展的组,分别(术中,0.05)。改变数字疼痛量表−1.17(3.17),−1.61(2.29),国际旅游展−1.35(2.42)和0.00(3.29),(3.07)和0.24−0.04(3.69)在CMM集团实际,分别至少和严重疼痛。实际的变化是重要的和最不痛苦(术中,0.05)。EQ-5D效用分数提高的生活质量评估的国际旅游展的病人相比0.09 (0.26)0.01 (0.16)CMM集团(术中,0.05)。EQ-5D健康状况得分增加了9.68(20.42)和4.40(21.75)在CMM国际旅游展的集团(P> 0.05)。 In total 17 (68%) ITB implanted patients reported at least one treatment-related adverse events versus 7 (20%) in CMM group. Most frequent drug reactions were muscular weakness (16% of patients), hypotonia (12%), fall (12%) and urinary retention (12%) in implanted patients and somnolence (9%) in CMM group.Conclusions: The study demonstrated superiority of ITB therapy versus conventional oralmedication in decreasing muscle hypertonia in post-stroke patients with spasticity. This also resulted in improvement of pain and quality of life in ITB patients.Study Supported by: MedtronicDisclosure: Dr. Yochelson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Best Doctors. Dr. Yochelson has received research support from Helius Medical Technologies, payment to MedStar National Rehabilitation Network, as I was PI for clinical trail. Dr. Creamer has nothing to disclose. Dr. Cloud has nothing to disclose. Dr. Kossmehl has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merz Pharmaceuticals GmbH, ASKLEPIOS Fachklinikum Teupitz. Dr. Francisco has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Ipsen, Merz, Medtronic. Dr. Francisco has received personal compensation in an editorial capacity for Journal of Rehabilitation Medicine. Dr. Francisco has received research support from Allergan, Ipsen, Merz, Medtronic, Microtransponder, Ottobock. Dr. Ward has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Ipsen. Dr. Wissel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Ipsen, Medtronic, Merz. Dr. Zampolini has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Medtronic. Dr. Loven has nothing to disclose. Dr. Abouihia has nothing to disclose. Dr. Calabrese has nothing to disclose. Dr. Saltuari has nothing to disclose.